BeOne Medicines has signed a multi-part collaboration with Revolution Medicines to develop and commercialise targeted oncology therapies.

The deal includes joint studies combining BeOne’s cancer pipeline assets with four clinical-stage RAS(ON) inhibitors from Revolution Medicines, alongside a regional rights agreement for select Asian markets.

The clinical partnership will focus on developing combination therapies for patients with RAS-addicted cancers.

It will evaluate combinations such as BeOne’s MTA-cooperative protein arginine methyltransferase 5 (PRMT5) inhibitor, BGB-58067, and a trispecific epidermal growth factor receptor × mesenchymal epithelial transition factor × mesenchymal epithelial transition factor (EGFR × MET × MET) antibody, BG-T187.

They will be studied alongside Revolution Medicines’ RAS(ON) inhibitor assets, daraxonrasib; zoldonrasib; elironrasib; and RMC-5127.

Planned studies will explore potential targeted therapy approaches using these combinations.

In a separate component of the arrangement, Revolution Medicines has granted BeOne exclusive rights to develop and commercialise, or solely commercialise, according to territory, its four RAS(ON) inhibitors in certain Asian regions.

The agreement stipulates that Revolution Medicines will receive development and sales milestone payments, along with tiered royalties on net sales from these territories.

Revolution Medicines retains all development and commercial rights for the products outside the licensed regions, notably including Japan and South Korea.

BeOne will also be responsible for funding and conducting a global registrational Phase III trial for one of the Revolution Medicines’ RAS(ON) inhibitors, utilising its internal development resources.

Revolution Medicines will continue to pursue global registrational studies across its broader portfolio.

BeOne co-founder, chairman, and CEO John Oyler said: “We are pleased to enter this collaboration with Revolution Medicines, which gives BeOne the opportunity to evaluate combinations between assets from our oncology pipeline and four promising RAS(ON) inhibitors from Revolution Medicines.

“In parallel, the regional rights transaction allows us to use our global development superhighway capabilities and established commercial presence, with the goal of bringing more medicines to patients with difficult-to-treat cancers.”

In August 2025, BeOne’s investigational Bruton’s tyrosine kinase (BTK) degrader, BGB-16673, received priority medicines (PRIME) designation from the European Medicines Agency to treat Waldenstrom’s macroglobulinemia in individuals previously treated with a BTK inhibitor.